71 -2 (88) 2026 - Khamidova F.M., Toirov B.A. - PHOTOBIOMODULATION (LLLT) IN THE TREATMENT OF ATOPIC DERMATITIS: IMMUNOPATHOGENETIC MECHANISMS AND CLINICAL EFFECTIVENESS

PHOTOBIOMODULATION (LLLT) IN THE TREATMENT OF ATOPIC DERMATITIS: IMMUNOPATHOGENETIC MECHANISMS AND CLINICAL EFFECTIVENESS

Khamidova F.M. - Samarkand State Medical University

Toirov B.A. - Tashkent International University of Chemistry

Tolibov M.M. - Samarkand State Medical University

Resume

Atopic dermatitis is a common chronic inflammatory skin disease characterized by recurrent course, marked skin itching, and impaired epidermal barrier function. Frequent relapses and limitations in standard therapy necessitate the search for safe and pathogenetically justified adjuvant treatment methods. The purpose of this review was to analyze and summarize modern literature data on the immunopathogenetic mechanisms of photobiomodulation (low-intensity laser therapy, LLLT) and its clinical effectiveness in atopic dermatitis. A review of domestic and foreign publications, including experimental and clinical studies of photobiomodulation, has been conducted. It has been shown that LLLT has a modulating effect on the key pathogenetic links of the disease, including inflammation, neurogenic mechanisms of itching, and skin barrier restoration processes, and can contribute to a reduction in the severity of clinical manifestations with a good safety profile. Photobiomodulation is considered a promising adjuvant method for complex therapy of atopic dermatitis, however, it requires further systematic research to determine the optimal application regimens and place in clinical practice.

Keywords: atopic dermatitis, photobiomodulation, low-intensity laser therapy, LLLT, pathogenesis.

First page

351

Last page

355

For citation:Khamidova F.M., Toirov B.A., Tolibov M.M. - PHOTOBIOMODULATION (LLLT) IN THE TREATMENT OF ATOPIC DERMATITIS: IMMUNOPATHOGENETIC MECHANISMS AND CLINICAL EFFECTIVENESS//New Day in Medicine 2(88)2026 356-362 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–1258. doi:10.1016/j.jaci.2009.10.009
2. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284–1293. doi:10.1111/all.13401
3. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1
4. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494. doi:10.1056/NEJMra074081
5. Simpson EL. Pathogenesis of atopic dermatitis: Recent developments. Allergy Asthma Proc. 2012;33(Suppl 1):S1–S4.
6. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron–expressed IL-31 receptor mediates T-helper cell–dependent itch. J Allergy Clin Immunol. 2014;133(2):448–460.
7. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis. J Allergy Clin Immunol. 2009;124(1):R14–R26.
8. Proksch E, Brandner JM, Jensen JM. The skin: An indispensable barrier. Exp Dermatol. 2008;17(12):1063–1072. doi:10.1111/j.1600-0625.2008.00786.x
9. Breuer K, Paci A, Poncet P, et al. Staphylococcus aureus colonization in atopic dermatitis. J Allergy Clin Immunol. 2002;110(2):234–239.
10. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi:10.1016/j.jaad.2013.10.010

    file

    download